Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab in COVID-19 pneumonia
NCT04492514Phase 2Completed
- Start
- May 2020
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of mavrilimumab in COVID-19 pneumonia. Started May 2020; status: completed.
02
Drugs
mavrilimumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04492514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492514.